Structure of Dasatinib HCl
CAS No.: 854001-07-3
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP-competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity, having Kis of 16 pM and 30 pM for Src and Bcr-Abl, respectively. It inhibits Bcr-Abl and Src with IC50 values of <1.0 nM and 0.5 nM, respectively, and induces apoptosis and autophagy.
Synonyms: BMS-354825 hydrochloride; Dasatinib hydrochloride; BMS-354825 HCl
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 854001-07-3 |
Formula : | C22H27Cl2N7O2S |
M.W : | 524.47 |
SMILES Code : | O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C.[H]Cl |
Synonyms : |
BMS-354825 hydrochloride; Dasatinib hydrochloride; BMS-354825 HCl
|
MDL No. : | MFCD26960525 |
InChI Key : | MSCGWICDJYLQOJ-UHFFFAOYSA-N |
Pubchem ID : | 11466607 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
K562 chronic myeloid leukemia cells | 0.1 nM | 24 or 48 h | Dasatinib reduced the total exosome release from K562 cells | PMC3595015 |
SUM149 | 25 nM | 24 and 72 h | Inhibit nEGFR translocation and enhance non-nuclear EGFR levels | PMC4013210 |
K562 leukemia cells | 10nM | Inhibited BCR-ABL1 signaling and reduced leukemia stem cell self-renewal potential | PMC4975616 | |
KG-1 cells | 100 nM | Inhibit Src kinase activity and reduce cell proliferation | PMC3228896 | |
BaF3 cells | 10 nM and 100 nM | 72 h | Inhibit Src kinase activity and reduce cell proliferation | PMC3228896 |
MDAMB468 | 25 nM | 24 and 72 h | Inhibit nEGFR translocation and enhance non-nuclear EGFR levels | PMC4013210 |
SUM229 | 25 nM | 24 and 72 h | Inhibit nEGFR translocation and enhance non-nuclear EGFR levels | PMC4013210 |
RL-95 cells | 100 nM | 48 h | Evaluate the effect of Dasatinib on p-p44/42 MAPK | PMC8511168 |
Normal CD34+ progenitors | 10nM | Combined with JAK2 inhibitor to inhibit self-renewal potential | PMC4975616 | |
SU-DHL-8 cells | 100 nM | 24 h | To assess the inhibitory effect of dasatinib on CD19-TCB-mediated target-cell killing. Results showed that 100 nM dasatinib significantly inhibited target-cell killing. | PMC8323395 |
MKN45 cells | 100 nM | 3 days | To assess the inhibitory effect of dasatinib on CEA-TCB-mediated target-cell killing. Results showed that 100 nM dasatinib significantly inhibited target-cell killing. | PMC8323395 |
A375 cells | 100 nM | 24 h | To assess the inhibitory effect of dasatinib on HLA-A2 WT1-TCB-mediated target-cell killing. Results showed that 100 nM dasatinib significantly inhibited target-cell killing. | PMC8323395 |
SKM-1 cells | 50 nM | 24 h | To assess the inhibitory effect of dasatinib on HLA-A2 WT1-TCB-mediated target-cell killing. Results showed that 50 nM dasatinib significantly inhibited target-cell killing. | PMC8323395 |
REH GCR cells | 100-300 nM | 48 h | Dasatinib combined with dexamethasone increased apoptosis, with Bliss synergy analysis showing additive effects (mean synergy score: 8.8). | PMC10203345 |
NALM6 cells | 100-300 nM | 48 h | Dasatinib combined with dexamethasone significantly increased apoptosis, with Bliss synergy analysis showing high synergy (mean synergy score: 30.8). | PMC10203345 |
PS125 cells | 3nM or 10nM | 24 h | Dasatinib alone at 3nM had no effect on PS125 cell viability, but showed synergistic effect when combined with AT9283. | PMC4179499 |
D556 cells | 1, 5, 10, 50 and 100nM | 1-24 h | Dasatinib markedly decreased p-Src levels, with near ablation of detectable p-Src following treatment with 5 and 10nM. | PMC4179499 |
DAOY cells | 1, 5, 10, 50 and 100nM | 1-24 h | Dasatinib markedly decreased p-Src levels, with near ablation of detectable p-Src following treatment with 5 and 10nM. | PMC4179499 |
human K562 cells | 5 nM | 48 h | Evaluate the effect of Dasatinib on cell viability, results showed Dasatinib fully suppressed cell growth | PMC4017764 |
human SUP-B15 cells | 5 nM | 48 h | Evaluate the effect of Dasatinib on cell viability, results showed Dasatinib fully suppressed cell growth | PMC4017764 |
mouse p190 BCR-ABL transformed hematopoietic progenitors | 5 nM | 48 h | Evaluate the effect of Dasatinib on cell viability, results showed Dasatinib fully suppressed cell growth | PMC4017764 |
human bone marrow-derived mesenchymal stem cells (BM-MSCs) | 1 μM | 21 days | To evaluate the effect of Dasatinib on adipogenesis in BM-MSCs. Results showed that Dasatinib reduced adipogenesis, decreasing the number and proportion of ORO-positive cells. | PMC10436421 |
Ishikawa cells | 100 nM | 48 h | Evaluate the effect of Dasatinib on p-p44/42 MAPK, results showed slight induction of pMAPK | PMC8511168 |
HEC-1A cells | 100 nM | 48 h | Evaluate the effect of Dasatinib on p-p44/42 MAPK, results showed slight induction of pMAPK | PMC8511168 |
Human umbilical vein endothelial cells (HUVEC) | 10 nM | 30 min | Dasatinib markedly inhibited HUVEC response to exosomes | PMC3595015 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Humanized NSG mice | Humanized NSG mouse model | Oral | 50 mg/kg | Three times on day 0 and twice on days 1 and 2 | To assess the inhibitory effect of dasatinib on CD19-TCB-mediated B cell depletion and cytokine release. Results showed that 50 mg/kg dasatinib significantly inhibited B cell depletion and cytokine release. | PMC8323395 |
C7BL/6 mice | Mouse flank syngeneic MB tumor model | Oral gavage | 15 mg/kg/day | Once daily for 5 consecutive days per week for 4 weeks | Dasatinib treatment resulted in significant reduction in MB tumor volume, with significantly lower tumor volumes compared to controls after 20 days of treatment. | PMC4179499 |
Mice | SUP-B15-luciferase xenograft model | Oral | 2.5 mg/kg | Daily doses throughout the full treatment duration | Evaluate the effect of Dasatinib alone or in combination with PP242 on leukemic cell expansion, results showed combination treatment caused regression of leukemic disease | PMC4017764 |
Mice (BKS.Cg-+Leprdb/+Leprdb/OlaHsd (db/db)) | Obese type 2 diabetes model | Oral gavage | 5 mg/kg | Once per week for four weeks | To assess the effect of Dasatinib on cardiac lipid deposition and function. Results showed that Dasatinib reduced lipid accumulation in the heart and bone marrow, improved diastolic function indices (E/A ratio and non-flow time), and decreased cardiac fibrosis and expression of the senescence marker p16. | PMC10436421 |
Nude mice | HEC-1A orthotopic model | Oral | 15 mg/kg | Daily until the end of the experiment | Evaluate the antitumor effect of Dasatinib alone or in combination with Trametinib, results showed that combination treatment significantly enhanced antitumor response | PMC8511168 |
RAG2−/−γc−/− mice | Humanized BC CML mouse model | Oral gavage | 50 mg/kg | Daily for two weeks | Inhibited BC LSC survival and self-renewal, prolonged survival of serially transplanted mice | PMC4975616 |
BALB/c nude mice | Matrigel plug model | Oral | 20 mg/kg | Once daily for 14 days | Dasatinib abrogated K562 exosome-induced angiogenesis | PMC3595015 |
Balb/c mice | ZNF112 and CEP2A cell transplantation model | Oral | 20 mg/kg and 40 mg/kg | 6 days per week for 4 weeks | Inhibit Src kinase activity and prolong survival | PMC3228896 |
Athymic nude mice | MDAMB468 xenograft model | Oral gavage | 50 mg/kg | Once daily for 4 days | Inhibit nEGFR translocation and enhance membrane EGFR accumulation | PMC4013210 |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.91mL 0.38mL 0.19mL |
9.53mL 1.91mL 0.95mL |
19.07mL 3.81mL 1.91mL |
Tags: Dasatinib | BMS-354825 | BMS354825 | BMS 354825 | Bcr-Abl | Src | Autophagy | Apoptosis | orally | active | antitumor | antiproliferative | K562 | CML | PC3 | prostate | MDA-MB-231 | breast | WiDr | colon | Inhibitor | Dasatinib hydrochloride | tyrosine kinase inhibitor | BCR-ABL inhibitor | CML | ALL | Nalm-6 | chronic myelogenous leukemia | acute lymphoblastic leukemia | resistance to imatinib | 854001-07-3
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL